1. A double blind, randomised, controlled trial of glutamine supplementation in parenteral nutrition
- Author
-
H V Fawcett, G. E. A. Bettany, D L Murphy, J Powell-Tuck, Omar Obeid, C.P. Jamieson, and C. Archer
- Subjects
Adult ,Male ,medicine.medical_specialty ,Parenteral Nutrition ,Adolescent ,Critical Care ,Glutamine ,Gastroenterology ,law.invention ,Double blind ,Randomized controlled trial ,Double-Blind Method ,law ,Interquartile range ,Internal medicine ,Intensive care ,Cause of Death ,Medicine ,Humans ,Hospital Mortality ,Cause of death ,Aged ,Aged, 80 and over ,Postoperative Care ,business.industry ,Length of Stay ,Middle Aged ,Surgery ,Parenteral nutrition ,Treatment Outcome ,Glutamine supplementation ,Commentary ,Female ,business - Abstract
Background and aims—To determine whether the inclusion of 20 g free glutamine as part of the nitrogen source of parenteral feeds reduces length of hospital stay or mortality. Methods—In a randomised, double blind, controlled trial in 168 patients clinically accepted for parenteral nutrition, standard feeds were compared with feeds in which 3.8 g of the total nitrogen was replaced with the equivalent 20 g glutamine. A minimum of 11 g nitrogen/ day was used in all patients. Daily intakes of energy and nitrogen were determined using a validated computer protocol and were similar for the two groups. All feeds included trace elements, vitamins, electrolytes, and minerals. Results—A total of 85 patients received a median of eight (interquartile range 5‐13) daily feeds containing glutamine while 83 received a median of eight (5‐15) standard feeds. No diVerence between groups was detected for infective complications. Twenty control patients and 14 who had received glutamine died during their hospital stay (NS). Median length of stay was 32 (23‐52) days on glutamine, which was not significantly diVerent from the control value of 35 (25‐55) days. Glutamine was associated with a significant (p
- Published
- 1999